权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Genomics Core

基因组学核心

基本信息

批准号：
10490401
负责人：
Jill A. Macoska
金额：
$ 13.19万
依托单位：
UNIVERSITY OF MASSACHUSETTS BOSTON
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-28 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10490401
关键词：
Address African American African ancestry Androgen Receptor BRCA2 gene Bioinformatics Biomedical Research Biostatistical Methods Boston CHD1 gene Cancer Biology Cancer Center Code DNA Sequence Dana-Farber Cancer Institute Data Data Analyses Education and Outreach Educational workshop Fees Frequencies Genomic approach Genomics Goals Infrastructure Institution Instruction Lead Learning Malignant neoplasm of prostate Massachusetts Minority-Serving Institution Modeling Outcome Population Prostatic Neoplasms RNA Receptor Signaling Research Research Design Research Personnel Research Training Resources Reverse Transcriptase Polymerase Chain Reaction Risk SNP genotyping Structure Students Technology Training Underrepresented Populations Underrepresented Students Universities Untranslated RNA anticancer research base cancer health disparity cancer initiation cancer risk cost design education research experience genomic data health disparity populations innovation instrumentation men nano-string next generation sequencing novel personalized cancer therapy programs single cell sequencing therapy resistant tool tumor progression

项目摘要

SUMMARY A critical gap often exists at institutions serving underserved health disparity populations and underrepresented students (ISUPS) between access to Genomics technologies and the high costs associated with the required instrumentation, technical proficiency, and analytical expertise. The Genomics Core (GC) addresses this gap by providing expert and affordable access to high-throughput genomics technologies on a reduced fee basis for all Partnership investigators. The GC benefits the entire Partnership by providing innovative approaches to explore early project ideas, and by working with Partnership investigators and their trainees to facilitate the use of genomics technologies to build sustainable cancer biology and cancer disparities research. To accomplish these goals, the GC (through the auspices of the Center for Personalized Cancer Therapy, CPCT) provides front-line genomics-related technologies, as well as bioinformatics support for data analysis, to Partnership investigators through an affordable reimbursement model. The GC proposes to accomplish these goals through the pursuit of four specific aims designed to build capacity for biomedical and cancer research and training at UMass Boston by bridging a gap in the availability of cutting-edge genomics-based tools; support Partnership investigators who wish to pursue early project ideas, especially those that require innovative and/or technically challenging genomics approaches; bridge a training gap between students and high-level genomics-based technologies, and provide bioinformatics analysis of data generated in the core. In this application, the GC specifically supports FP2: Targeting androgen receptor signaling in prostate cancer in men with African Ancestry – Steven Balk (DF/HCC - BIDMC) and Changmeng Cai (UMass Boston) and PP2: High frequency of CHD1 loss in BRCA2-deficient African American prostate tumors drives treatment resistance – Zoltan Szallasi (DF/HCC - BCH) and Shailja Pathania (UMass Boston).

总结